Egyesült Államok - angol - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - cephapirin benzathine (unii: 90g868409o) (cephapirin - unii:89b59h32vn) - for the treatment of mastitis in dairy cows during the dry period. tomorrow has been shown by extensive clinical studies to be efficacious in the treatment of mastitis in dry cows, when caused by streptococcus agalactiae and staphylococcus aureus including penicillin-resistant strains. treatment of the dry cow with tomorrow is indicated in any cow known to harbor any of these organisms in the udder at drying off. indicaciones para el tratamiento de mastitis bovina durante el período seco. extensos estudios clínicos han demostrado que tomorrow es eficaz en el tratamiento de la mastitis en vacas secas, cuando ésta es causada por el streptococcus agalactiae y el staphylococcus aureus, incluyendo cepas resistentes a la penicilina. el tratamiento de la vaca seca con tomorrow es recomendado para cualquier vaca que se sepa alberga a cualquiera de estos organismos en la ubre al momento del período de secado.

Szingapúr - angol - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - rabies virus (wistar rabies pm/wi 38-1503-3m strain) - injection, powder, for solution - min 2.5 iu/vial

Európai Unió - angol - myHealthbox

pfizer limited - crizotinib - hard capsules - 200 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

Európai Unió - angol - myHealthbox

pfizer limited - crizotinib - hard capsules - 250 mg - carcinoma, non-small-cell lung - anti-neoplastic agents, protein kinase inhibitor - indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk)-positive advanced non-small cell lung cancer (nsclc)

Málta - angol - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - streptococcus pneumoniae - solution for injection - streptococcus pneumoniae 25 µg - vaccines

Málta - angol - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid, diphtheria toxoid, haemophilus type, b polysaccharide, polyribosylribitol phosphate, conjugated to, as carrier, protein, bordetella pertussis - powder and suspension for suspension for injection - diphtheria toxoid haemophilus type b polysaccharide (polyribosylribitol phosphate) conjugated to tetanus toxoid as carrier protein 10 µg bordetella pertussis 4 iu tetanus toxoid 60 iu - vaccines

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutinib (as monohydrate) - leukemia, myeloid - antineoplastic agents, protein kinase inhibitors - bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (cp) philadelphia chromosome-positive chronic myelogenous leukaemia (ph+ cml).cp, accelerated phase (ap), and blast phase (bp) ph+ cml previously treated with one or more tyrosine kinase inhibitor(s) [tki(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - varenicline - tobacco use cessation - other nervous system drugs - champix is indicated for smoking cessation in adults.

Európai Unió - angol - EMA (European Medicines Agency)

pfizer europe ma eeig - bazedoxifene - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. a significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.when determining the choice of conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.

Európai Unió - angol - EMA (European Medicines Agency)

basilea pharmaceutica deutschland gmbh - isavuconazole - aspergillosis - cresemba is indicated in adults for the treatment of:invasive aspergillosismucormycosis in patients for whom amphotericin b is inappropriateconsideration should be given to official guidance on the appropriate use of antifungal agents.